乳腺癌新辅助内分泌治疗的研究进展

Neoadjuvant endocrine therapy of breast cancer

目的:通过文献复习总结目前乳腺癌新辅助内分泌治疗研究的新进展,探讨目前乳腺癌新辅助内分泌治疗研究中的问题及未来发展趋势。方法:应用HighWire、PubMed及CNKI期刊全文数据库检索系统,以"乳腺癌、他莫昔芬、芳香化酶抑制剂和新辅助内分泌治疗"为关键词,检索2000-2010年的相关文献,共检索到英文文献526条。纳入标准:1)乳腺癌的新辅助内分泌治疗。2)他莫昔芬在新辅助内分泌治疗中的应用;3)芳香化酶抑制剂在新辅助内分泌治疗的应用。4)乳腺癌新辅助内分泌治疗综合评价。根据纳入标准,符合分析的文献21篇。结果:乳腺癌新辅助内分泌治疗是最近几年才提出的一种乳腺癌治疗手段,对于雌孕激素受体阳性乳腺癌患者的辅助治疗较化疗有独特的优势。但新辅助内分泌治疗目前尚未成为乳腺癌的常规治疗方法。结论:新辅助内分泌治疗相关的治疗适用对象、治疗药物的选择、用药周期和剂量、疗效评估等多个内容目前仍处于探索阶段。

OBJECTIVE：To explore the recent advance in neoadjuvant endocrine therapy of breast cancer.METHODS：Totally 526 papers published during 2000-2010 were searched with key words or subject words ＂breast neoplasm,neoadjuvant endocrine treatment,tamoxifen,and aromtase inhibitor＂,respectively or in combination,from CNKI,MEDLINE and HighWire databases.Inclusion criteria： 1）neoadjuvant endocrine treatment of breast cancer.2）neoadjuvant treatment of breast cancer with tamoxifen.3）aromtase inhibitor and breast cancer neoadjuvant treatment.4）methods of comprehensive evaluation in breast cancer neoadjuvant treatment.According to the inclusion criteria,21 papers were finally analyzed and reviewed.RESULTS： As an emerging treatment of breast cancer,neoadjuvant endocrine therapy has shown unique superiority over neochemotheray.However,neoadjuvant endocrine therapy has not yet been accepted as a regular treatment of breast cancer.CONCLUSION： The factors affecting neoadjuvant endocrine therapy to be accepted as a regular treatment of breast cancer patients are： the patient population that should receive neoadjuvant endocrine therapy,the agents that suitable for neoadjuvant endocrine therapy,and their related dosage and duration,evaluation and so on.